Moberg Pharma and DongKoo Sign Agreement for MOB-015 in the Republic of Korea

0
714

 

Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with DongKoo Bio & Pharma Co., Ltd for MOB-015 in the Republic of Korea. Under the agreement DongKoo is granted exclusive rights to market and sell MOB-015 in the Republic of Korea. Moberg Pharma assumes production and supply responsibility.

DongKoo will conduct registration activities in the Republic of Korea, and will be marketing, distributing and selling MOB-015 in the Republic of Korea upon completion of registration.

This is the fourth commercial agreement for MOB-015, this time with the market leader in dermatology in Korea with excellent coverage of the dermatology clinics. We look forward to work with DongKoo and making MOB-015 available in Korea, contributing to our vision of making MOB-015 the leading nail fungus treatment worldwide“, says Anna Ljung, CEO of Moberg Pharma.

According to Moberg Pharma’s market intelligence, the Korean market for topical drugs for onychomycosis amounts to $40 million (rolling 12m ending June 2019).

 

SOURCE Moberg Pharma

LEAVE A REPLY

Please enter your comment!
Please enter your name here